Boron tumor delivery for BNCT: Recent developments and perspectives

Boron Science: New Technologies and Applications

Volumn , Issue , 2016, Pages 209-241

  Sibrian Vazquez, Martha ^a   Vicente, Maria da Graça H ^b  

^a PORTLAND STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85053022583     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (195)

1. Hawthorne, M. F. The role of chemistry in the development of boron neutron-capture therapy of cancer. Angew. Chem. Int. Ed. Eng. 1993, 32, 950-984.
2. Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Rong, F. G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. The chemistry of neutron capture therapy. Chem. Rev. 1998, 98, 1515-1562.
3. Barth, R. F.; Soloway, A. H.; Goodman, J. H.; Gahbauer, R. A.; Gupta, N.; Blue, T. E.; Yang, W. L.; Tjarks, W. Boron neutron capture therapy of brain tumors: An emerging therapeutic modality. Neurosurg. 1999, 44, 433-451.
4. Barth, R. F.; Coderre, J. A.; Vicente, M. G. H.; Blue, T. E. Boron neutron capture therapy of cancer: Current status and future prospects. Clin. Cancer Res. 2005, 11, 3987-4002.
5. Barth, R. F.; Joensuu, H. Boron neutron capture therapy for the treatment of gliobtastomas and extracranial tumours: As effective, more effective or less effective than photon irradiatioň Rad. Oncol. 2007, 82, 119-122.
6. Diaz, A. Z. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J. Neuro-Oncol. 2003, 62, 101-109.
7. Busse, P. M.; Harling, O. K.; Palmer, M. R.; Kiger III, W. S.; Kaplan, J.; Kaplan, I.; Chuang, C. F., et al., A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J. Neuro-Oncol. 2003, 62, 111-121.
8. Nakagawa, Y.; Pooh, K.; Kobayashi, T.; Kageji, T.; Uyama, S.; Matsumura, A.; Kumada, H. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J. Neuro-Oncol. 2003, 62, 87-99.
9. Hideghety, K.; Sauerwein, W.; Wittig, A.; Gotz, C.; Paquis, P.; Grochulla, F.; Haselsberger, K., et al., Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. J. Neuro-Oncol. 2003, 62, 145-156.
10. Joensuu, H.; Kankaanranta, L.; Seppala, T.; Auterinen, I.; Kallio, M.; Kulvik, M.; Laakso, J., et al., Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J. Neuro-oncol. 2003, 62, 123-134.
11. Capala, J.; Stenstam, B. H.; Skold, K.; af Rosenschold, P. M.; Giusti, V.; Persson, C.; Wallin, E., et al., Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J. Neuro-Oncol. 2003, 62, 135-144.
12. Vitale, A. A.; Hoffman, G.; Pomilio, A. B. Boron-containing bioactive molecules: An approach to boron neutron capture therapy. Mol. Med. Chem. 2005, 8, 1-49.
13. Yamamoto, T.; Nakai, K.; Matsumura, A. Boron neutron capture therapy for glioblastoma. Cancer Lett. 2008, 2, 143-152.
14. Bregadze, V. I.; Sivaev, I. B.; Glazun, S. A. Polyhedral Boron Compounds as Potential Diagnostic and Therapeutic Antitumor Agents. Curr. Med. Chem., Anti-Cancer Agents 2006, 6, 75-110.
15. Sivaev, I. B.; Bregadze, V. I. Polyhedral Boranes for Medical Applications: Current Status and Perspectives. Eur. J. Inorg. Chem. 2009, 11, 1433-1450.
16. Fairchild, R. G.; Bond, V. P. Current status of b-10-neutron capture therapy -enhancement of tumor dose via beam filtration and dose-rate, and the effects of these parameters on minimum boron content -a theoretical evaluation. Int. J. Radiat. Oncol. Biol. Phys. 1985, 11, 831-840.
17. Gabel, D.; Foster, S.; Fairchild, R. G. The monte-carlo simulation of the biological effect of the b-10(n,alpha)li-7 reaction in cells and tissue and its implication for boron neutron-capture therapy. Radiat. Res. 1987, 111, 14-25.
18. Sibrian-Vazquez, M.; Hao, E.; Jensen, T. J.; Vicente, M. G. H. Enhanced cellular uptake with a cobaltacarborane-porphyrin-HIV-1 Tat 48-60 conjugate. Bioconj. Chem. 2006, 17, 928-934.
19. Barth, R. F.; Wu, G.; Yang, W.; Binns, P. J.; Riley, K. J.; Patel, H.; Coderre, J. A., et al., Neutron capture therapy of epidermal growth factor (plus) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl. Rad. Isotopes 2004, 61, 899-903.
20. Burgess, A. W. EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors 2008, 26, 263-274.
21. Barth, R. F. Boron neutron capture therapy at the crossroads: Challenges and opportunities. Appl. Rad. Isotopes 2009, 67, S3-S6.
22. Ferguson, S.; Lesniak, M. S. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr. Drug Deliv. 2007, 4, 169-180.
23. Barth, R. F.; Yang, W. L.; Al-Madhoun, A. S.; Johnsamuel, J.; Byun, Y.; Chandra, S.; Smith, D. R.; Tjarks, W.; Eriksson, S. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res. 2004, 64, 6287-6295.
24. Ozawa, T.; Santos, R. A.; Lamborn, K. R.; Bauer, W. F.; Koo, M.-S.; Kahl, S. B.; Deen, D. F. In vivo evaluation of the boronated porphyrin TABP-1 in U-87 MG intracerebral human glioblastoma xenografts. Mol. Pharm.2004, 1, 368-374.
25. Ozawa, T.; Afzal, J.; Lamborn, K. R.; Bollen, A. W.; Bauer, W. F.; Koo, M. S.; Kahl, S. B.; Deen, D. F. Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. Int. J. Rad. Oncol. Biol. Phys. 2005, 63, 247-252.
26. Kawabata, S.; Barth, R. F.; Yang, W. L.; Wu, G.; Gottumukkala, V.; Vicente, M. G. H. Proc. 13th World Congress of Neurological Surgery 2005, 1, 975-979.
27. Kawabata, S.; Barth, R. F.; Yang, W.; Wu, G.; Binns, P. J.; Riley, K. J.; Ongayi, O.; Gottumukkala, V.; Vicente, M. G. H. Proc. 12th International Congress on Neutron Capture Therapy for Cancer 2006, 1, 123-126.
28. Kawabata, S.; Yang, W.; Barth, R. F.; Wu, G.; Huo, T.; Binns, P. J.; Riley, K. J.; Ongayi, O.; Gottumukkala, V.; Vicente, M. G. H., Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors. J Neurooncol. 2010, DOI 10.1007/s11060-010-0376-5.
29. Yang, W.; Barth, R. F.; Wu, G.; Huo, T.; Tjarks, W.; Ciesielski, M.; Fenstermaker, R. A., et al. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J. Neuro-oncol. 2009, 95, 355-365.
30. Barth, R. F.; Yang, W.; Rotaru, J. H.; Moeschberger, M. L.; Joel, D. D.; Nawrocky, M. M.; Goodman, J. H.; Soloway, A. H. Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 1997, 57, 1129-1136.
31. Barth, R. F.; Yang, W.; Rotaru, J. H.; Moeschberger, M. L.; Boesel, C. P.; Soloway, A. H.; Joel, D. D.; Nawrocky, M. M.; Ono, K.; Goodman, J. H. Boron neutron capture therapy of brain tumors: Enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Intl. J. Radiat. Oncol. Biol. Phys. 2000, 47, 209-218.
32. Barth, R. F.; Yang, W.; Bartus, R. T.; Rotaru, J. H.; Ferketich, A. K.; Moeschberger, M. L.; Nawrocky, M. M.; Coderre, J. A.; Rofstad, E. K. Neutron capture therapy of intracerebral melanoma: Enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. Intl. J. Radiat. Oncol. Biol. Phys 2002, 52, 858-868.
33. Capuani, S.; Gili, T.; Bozzali, M.; Russo, S.; Porcari, P.; Cametti, C.; Muolo, M., et al. Boronophenylalanine uptake in C6 glioma model is dramatically increased by L-DOPA preloading. Appl. Rad. Isotopes 2009, 67, S34-S36.
34. Grimes, R. N. Carboranes; New York: Academic Press, 1970.
35. Bregadze, V. I. Dicarba-closo-dodecaboranes C2B10H12 and their derivatives. Chem. Rev. 1992, 92, 209-223.
36. Plesek, J.; Hermanek, S.; Franken, A.; Cisarova, I.; Nachtigal, C. Dimethyl sulfate induced nucleophilic substitution of the [bis(1,2-dicarbollido)-3-cobalt(1-)]ate ion. Syntheses, properties and structures of its 8,8'-mu-sulfato, 8-phenyl and 8-dioxane derivatives. Collect. Czech. Chem. Commun. 1997, 62, 47-56.
37. Teixidor, F.; Pedrajas, J.; Rojo, I.; Vinas, C.; Kivekas, R.; Sillanpaa, R.; Sivaev, I.; Bregadze, V.; Sjoberg, S. Methylation and demethylation in cobaltabis(dicarbollide) derivatives. Organometallics 2003, 22, 3414-3423.
38. Tiwari, R.; Mahasenan, K.; Pavlovicz, R.; Li, C.; Tjarks, W. Carborane clusters in computational drug design: a comparative docking evaluation using autodock, flexx, glide, and surflex. J. Chem. Inf. Model. 2009, 49, 1581-1589.
39. Sivaev, I. B.; Bregadze, V. I.; Kuznetsov, N. T. Derivatives of the closo-dodecaborate anion and their application in medicine. Russ. Chem. Bull. Int. Ed. 2002, 51, 1362-1365.
40. Gabel, D.; Harfst, S.; Moller, D.; Ketz, H.; Peymann, T.; Rosler, J. In Current Topics in the Chemistry of Boron, Kabalka, G. W. Ed., Cambridge: The Royal Society of Chemistry, 1994; pp. 161-164.
41. Matsumura, A.; Shibata, Y.; Yamamoto, T.; Yoshida, F.; Isobe, T.; Nakai, K.; Hayakawa, Y., et al. A new boronated porphyrin (STA-BX909) for neutron capture therapy: an in vitro survival assay and in vivo tissue uptake study. CancerLett. 1999, 141, 203-209.
42. Harfst, S.; Moller, D.; Ketz, H.; Rosler, J.; Gabel, D. Reversed-phase separation of ionic organoborate clusters by high-performance liquid-chromatography. J. Chromatogr. A 1994, 678, 41-48.
43. Ratajski, M.; Osterloh, J.; Gabel, D. Boron-Containing Chlorins and Tetraazaporphyrins: Synthesis and Cell Uptake of Boronated Pyropheophorbide A Derivatives. Curr. Med. Chem., Anti-Cancer Agents 2006, 6, 159-166.
44. Grin, M. A.; Semioshkin, A. A.; Titeev, R. A.; Nizhnik, E. A.; Grebenyuk, J. N.; Mironov, A. F.; Bregadze, V. I. Synthesis of a cycloimide bacteriochlorin p conjugate with the closo-dodecaborate anion. Mendeleev Comm. 2007, 17, 14-25.
45. Hao, E.; Friso, E.; Miotto, G.; Jori, G.; Soncin, M.; Fabris, C.; Sibrian-Vazquez, M.; Vicente, M. G. H. Synthesis and biological investigations of tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC). Org. Biomol. Chem. 2008, 6, 3732-3740.
46. Fabris, C.; Jori, G.; Giuntini, F.; Roncucci, G. J. Photosensitizing properties of a boronated phthalocyanine: studies at the molecular and cellular level. Photochem. Photobiol. B: Biol. 2001, 64, 1-7.
47. Semioshkin, A.; Tsaryova, O.; Zhidkova, O.; Bregadze, V.; Wohrle, D. Reactions of oxonium derivatives of (B12H12)2-with phenols, and synthesis and photochemical properties of a phthaloocyanine containing four (B12H12)2-groups. J. Porphyrins Phthalocyanines 2006, 10, 1293-1300.
48. Giovenzana, G. B.; Lay, L.; Monty, D.; Palmisano, G.; Panza, L. Synthesis of carboranyl derivatives of alkynyl glycosides as potential BNCT agents. Tetrahedron 1999, 55, 14123-14136.
49. Ronchi, S.; Prosperi, D.; Thimon, C.; Morinc, C.; Panza, L. Synthesis of mono-and bisglucuronylated carboranes. Tetrahedron: Asymmetry 2005, 16, 39-44.
50. Tietze, L. F.; Bothe, U.; Griesbach, U.; Nakaichi, M.; Hasegawa, T.; Nakamura, H.; Yamamoto, Y. ortho-Carboranyl glycosides for the treatment of cancer by boron neutron capture therapy. Bioorg. Med. Chem. 2001, 9, 1747-1752.
51. Orlova, A. V.; Zinin, A. I.; Malysheva, N. N.; Kononov, L. O.; Sivaev, I. B.; Bregadze, V. I. Conjugates of polyhedral boron compounds with carbohydrates. 1. New approach to the design of selective agents for boron neutron capture therapy of cancer. Russ. Chem.Bull., Int. Ed. 2003, 52, 2766-2768.
52. Orlova, A. V.; Kononov, L. O.; Kimel, B. G.; Sivaev, I. B.; Bregadze, V. I. Conjugates of polyhedral boron compounds with carbohydrates. 4. Hydrolytic stability of carborane-lactose conjugates depends on the structure of a spacer between the carborane cage and sugar moiety. Appl. Organometal. Chem. 2006, 20, 416-420.
53. Tietze, L. F.; Bothe, U. Ortho-carboranyl glycosides of glucose, mannose, maltose and lactose for cancer treatment by boron neutron-capture therapy. Chem. Eur. J. 1998, 4, 1179-1183.
54. Raddatz, S.; Marcello, M.; Kliem, H.-C.; Troster, H.; Trendelenburg, M. F.; Oeser, T.; Granzow, C.; Wiessler, M. Synthesis of new boron-rich building blocks for boron neutron capture therapy or energy-filtering transmission electron microscopy. Chem. Biol. Chem. 2004, 5, 474-482.
55. Kononov, L. O.; Orlova, A. V.; Zinin, A. I.; Kimel, B. G.; Sivaev, I. B.; Bregadze, V. I. Conjugates of polyhedral boron compounds with carbohydrates. 2. Unexpected easy closo-to nido-transformation of a carborane-carbohydrate conjugate in neutral aqueous solution. J. Organomet. Chem. 2005, 690, 2769-2774.
56. Tietze, L. F.; Bothe, U.; Schuberth, I. Preparation of a new carboranyl lactoside for the treatment of cancer by boron neutron capture therapy: Synthesis and toxicity of fluoro carboranyl glycosides for in vivo F-19-NMR spectroscopy. Chem. Eur. J. 2000, 6, 836-842.
57. Tietze, L. F.; Griebach, U.; Schuberth, I.; Bothe, U.; Marra, A.; Dondoni, A. Novel carboranyl C-glycosides for the treatment of cancer by boron neutron capture therapy. Chem. Eur. J. 2003, 9,1296-1302.
58. Basak, P.; Lowary, T. L. Synthesis of conjugates of L-fucose and ortho-carborane as potential agents for boron neutron capture therapy. Can. J. Chem. 2002, 80, 943-948.
59. Swenson, D. H.; Laster, B. H.; Metzger, R. L. Synthesis and evaluation of a boronated nitroimidazole for boron neutron capture therapy. J. Med. Chem. 1996, 39, 1540-1544.
60. Lechtenberg, B.; Gabel, D. Synthesis of a (B12H11S)(2-) containing glucuronoside as potential prodrug for BNCT. J. Organometal. Chem. 2005, 690, 2780-2782.
61. Meo, C. D.; Panza, L.; Capitani, D.; Mannina, L.; Banzato, A.; Rondina, M.; Renier, D.; Rosato, A.; Crescenzi, V. Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. Biomacromolecules 2007, 8, 552-559.
62. Scobie, M.; Threaddgill, M. D. Tumor-Targeted Boranes. 4. Synthesis Of Nitroimidazole-Carboranes With Polyether-Isoxazole Links. J. Org. Chem. 1994, 59, 7008-7013.
63. Wood, P. J.; Scobie, M.; Threaddgill, M. D. Uptake and retention of nitroimidazole-carboranes designed for boron neutron capture therapy in experimental murine tumours: Detection by B-11 magnetic resonance spectroscopy. Int. J. Radiat. Biol. 1996, 70, 587-592.
64. Schirrmacher, E.; Schirrmacher R.; Beck, C.; Mier, W.; Trautman, N.; Rosh, F. Synthesis of a Tyr(3)-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy. Tetrahedron Lett. 2003, 44, 9143-9145.
65. Mier, W.; Gabel, D.; Haberkorn, U.; Eisenhut, M. Z. Conjugation of the closo-borane mereaptoundecahydrododecaborate (BSH) to a tumour selective peptide. Anorg. Allg. Chem. 2004, 630, 1258-1262.
66. Justus, E.; Awad, D.; Hohnholt, M.; Schaffran, T.; Edwards, K.; Karlsson, G.; Damian, L.; Gabel, D. Synthesis, liposomal preparation, and in vitro toxicity of two novel dodecaborate cluster lipids for boron neutron capture therapy. Bioconjugate Chem. 2007, 18, 1287-1293.
67. Nakamura, H.; Lee J-D.; Ueno, M.; Miyajima, Y.; Ban, H-S. Nanobiotechnol. 2007, 3, 135-145.
68. Lee, J.-D.; Ueno, M.; Miyajima, Y.; Nakamura, H. Synthesis of boron cluster lipids: closo-dodecaborate as an alternative hydrophilic function of boronated liposomes for neutron capture therapy. Org. Lett. 2007, 9, 323-326.
69. Nakamura, H.; Ueno, M.; Ban, H.-S.; Nakai, K.; Tsuruta, K.; Kaneda, Y.; Matsumura, A. Development of boron nanocapsules for neutron capture therapy. Appl. Rad. Isotopes 2009, 67, S84-S87.
70. Diaz, S.; Gonzalez, A.; De Riancho, S. G.; Rodriguez, A. Boron complexes of S-trityl-L-cysteine and S-tritylglutathione. J. Organomet. Chem. 2000, 610, 25-30.
71. Lindstrom, P.; Naeslund, C.; Sjoberg S. Enantioselective synthesis and absolute configurations of the enantiomers of o-carboranylalanine. Tetrahedron Lett. 2000, 41, 751-754.
72. Masunaga, S.-I.; Ono, K.; Kirihata, M.; Takagaki, M.; Sakurai, Y.; Kinashi, Y.; Kobayashi, T., et al., Potential of alpha-amino alcohol p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, regarding its enantiomers. J. Cancer Res. Clin. Oncol. 2003, 129, 21-28.
73. Ujvary, I.; Nachman, R. J. Synthesis of 3-(12-hydroxy-p-carboranyl)propionic acid, a hydrophobic, N-terminal tyrosine-mimetic for peptides. Peptides 2001, 22, 287-290.
74. Beletskaya, I. P.; Bregadze, V. I.; Osipov, S. N.; Petrovskii, P. V.; Starikova, Z. A.; Timofeev, S. V. New nonnatural alpha-amino acid derivatives with carboranyl fragments in alpha-and beta-positions. Synlett 2004, 1247-1248.
75. Morin, C.; Thimon, C. Synthesis and evaluation of boronated lysine and bis(carboranylated) gamma-amino acids as monomers for peptide assembly. Eur. J. Org. Chem. 2004, 3828-3832.
76. Timofeev, S. V.; Bregadze, V. I.; Osipov, S. N.; Titanyuk, I. D.; Petrovskii, V.; Starikova, Z. A.; Glukhov, I. V.; Beletskayab, I. P. New carborane-containing amino acids and their derivatives. Crystal structures of n-protected carboranylalaninates. Russ. Chem. Bull. Int. Ed. 2007, 56, 791-797.
77. Semioshkin, A.; Nizhnik, E.; Godovikov, I.; Starikova, Z.; Bregadze, V. Reactions of oxonium derivatives of [B-12 H-12](2-) with amines: Synthesis and structure of novel B-12-based ammonium salts and amino acids. J. Organometallic Chem. 2007, 692, 4020-4028.
78. Kabalka, G. W.; Yao, M.-L. The synthesis and use of boronated amino acids for boron neutron capture therapy. Curr. Med. Chem. Anti-Cancer Agents 2006, 111-126.
79. Kabalka, G. W.; Yao, M.-L. Synthesis of 1-amino-3-[(dihydroxyboryl)methyl]-cyclobutanecarboxylic acid as a potential therapy agent. J. Org. Chem. 2004, 69, 8280-8286.
80. Kabalka, G. W.; Yao, M.-L. Synthesis of a novel boronated 1-aminocyclobutanecarboxylic acid as a potential boron neutron capture therapy agent. Appl. Organomet Chem 2003, 17, 398-402.
81. Kabalka, G. W.; Wu, Z. Z.; Yao, M.-L.; Natarajan, N. The syntheses and in vivo biodistribution of novel boronated unnatural amino acids. App. Rad. Isotopes 2004, 61, 1111-1115.
82. Kabalka, G. W.; Wu, Z.; Yao, M.-L. Synthesis of a series of boronated unnatural cyclic amino acids as potential boron neutron capture therapy agents. Appl. Organometal. Chem. 2008, 22, 516-522.
83. Kabalka, G. W.; Yao, M.-L.; Marepally, S. R.; Chandra, S. Biological evaluation of boronated unnatural amino acids as new boron carriers. App. Rad. Isotopes 2009, 67, S374-S379.
84. Sivaev, I. B.; Starikova, Z. A.; Sjoberg, S.; Bregadze, V. I. Synthesis of functional derivatives of the [3,3'-Co(1,2-C2B2H11)(2)](-) anion. J. Organomet. Chem. 2002, 649, 1-8.
85. Takagaki, M.; Powell, W.; Sood, A.; Spielvogel, B. F.; Hosmane, N. S.; Kirihata, M.; Ono, K., et al. Boronated dipeptide borotrimethylglycylphenylalanine as a potential boron carrier in boron neutron capture therapy for malignant brain tumors. Radiat Res. 2001, 156, 118-122.
86. Wakamiya, T.; Yamashita, T.; Fujii, T.; Yamaguchi, Y.; Nakano, T.; Kirihata, M. Syntheiss of 4-boronphenylalanine-containig peptides for boron neutron capture therapy of cancer cells. Peptide Sci. 1999, 36, 209-212.
87. Spielvogel, B. F.; Rana, G.; Vyakaranam, K.; Grelck, K.; Dicke, K. E.; Dolash, B. D.; Li, S.-J., et al., A novel approach to the syntheses of functionalized, water-soluble icosahedral carboranyl anions. Crystal structure of methyl N-[(trimethylamineboryl)carbonyl]-L-tyrosinate: A synthon for novel carboranylpeptides. Collect Czech Chem. Commun. 2002, 67, 1095-1108.
88. Ivanov, D.; Bachovchin, W. W.; Redfield, A. G. Boron-11 pure quadrupole resonance investigation of peptide boronic acid inhibitors bound to alpha-lytic protease. Biochemistry 2002, 41, 1587-1590.
89. Vives, E. Cellular uptake of the Tat peptide: an endocytosis mechanism following ionic interactions. J. Mol. Recog. 2003, 16, 265-271.
90. Shirakawa, M.; Yamamto, T.; Nakai, K,; Aburai, K.; Kawatobi, S.; Tsurubuchi, T.; Yamamoto, Y.; Yokoyama, Y.; Okuno, H.; Matsumura, A. Synthesis and evaluation of a novel liposome containing BPA-peptide conjugate for BNCT. Appl. Rad. Isotopes 2009, 67, S88-S90.
91. Tjarks, W. The use of boron clusters in the rational design of boronated nucleosides for neutron capture therapy of cancer J. Organomet. Chem. 2000, 614-615, 37-47.
92. Schinazi, R. F.; Hurwitz, S. J.; Liberman, I.; Juodawlkis, A. S.; Tharnish, P.; Shi, J.; Liotta, D. C.; Coderre, J. A.; Olson, J. Treatment of isografted 9L rat brain tumors with beta-5-o-carboranyl-2'-deoxyuridine neutron capture therapy. Clin. Cancer Res. 2000, 6, 725-730.
93. Al-Madhoun, A. S.; Johnsamuel, J.; Yan, J.; Ji, W.; Wang, J.; Zhuo, J.-C.; Lunato, A. J., et al., Synthesis of a small library of 3-(Carboranylalkyl)thymidines and their biological evaluation as substrates for human thymidine kinases 1 and 2. J. Med.Chem. 2002, 45, 4018-4028.
94. Yan, J.; Naeslund, C.; Al-Madhoun, A. S.; Wang, J.; Ji, W.; Cosquer, G. Y.; Johnsamuel, J.; Sjoberg, S.; Eriksson, S.; Tjarks, W. Synthesis and biological evaluation of 3'-Carboranyl thymidine analogues. Bioorg. Med. Chem. Lett. 2002, 12, 2209-2212.
95. Vyakaranam, K.; Rana, G.; Delaney, S.; Ledger, S.; Hosmane, N. S. The first carboranyl bis(adenosine diphosphate) (CBADP): a synthetic investigation. Inorg. Chem. Commun. 2003, 6, 654-657.
96. Olejniczak, A. B.; Semenuk, A.; Kwiatkowski, M.; Lesnikowski Z. J. Synthesis of adenosine containing carborane modification. J. Organomet. Chem. 2003, 680, 124-126.
97. Schinazi, R. F.; Hurwitz, S. J.; Liberman, I.; Glazkova, Y.; Mourier, N. S.; Olson, J.; Keane, T. Tissue disposition of 5-o-carboranyluracil -A novel agent for the boron neutron capture therapy of prostate cancer. Nucleosides, Nucleotides and Nucleic Acids 2004, 23, 291-306.
98. Johnsamuel, J.; Lakhi, N.; Al-Madhoun A. S.; Byun, Y.; Yan, J.; Eriksson, S.; Tjarks, W. Synthesis of ethyleneoxide modified 3-carboranyl thymidine analogues and evaluation of their biochemical, physicochemical, and structural properties. Bioorg. Med. Chem. 2004, 12, 4769-4781.
99. Al-Madhoun, A. S.; Johnsamuel, J.; Barth, R. F.; Tjarks, W.; Eriksson, S. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res. 2004, 64, 6280-6286.
100. Wojtczak, B.; Semenyuk, A.; Olejniczak, A. B.; Kwiatkowski, M.; Lesnikowski, Z. J. General method for the synthesis of 2'-O-carboranyl-nucleosides. Tetrahedron Lett. 2005, 46, 3969-3972.
101. Byun, Y.; Yan, J.; Al-Madhoun A. S.; Johnsamuel, J.; Yang, W.; Barth, R. F.; Eriksson, S.; Tjarks, W. Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy. J. Med. Chem. 2005, 48, 1188-1198.
102. Byun, Y.; Narayanasamy, S.; Johnsamuel, J.; Bandyopadhyaya, A. K.; Tiwari, R.; Al-Madhoun, A. S.; Barth, R. F.; Eriksson, S.; Tjarks, W. Curr. Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy Med. Chem. Anti-Cancer Agents 2006, 6, 127-144.
103. Byun, Y.; Thirumamagal, B. T. S.; Yang, W. L.; Eriksson, S.; Barth, R. F.; Tjarks, W. Preparation and biological evaluation of B-10-enriched 3-[5-(2-(2,3-dihydroxyprop-1-yl)-o-carboran-1-yl)pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors. J. Med. Chem. 2006, 49, 5513-5523.
104. Barth, R. F.; Yang, W.; Wu, G.; Swindall, M.; Byun, Y.; Narayanasamy, S.; Tjarks, W., et al., Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. Proc. Nat. Acad. Sci. USA 2008, 105, 17493-17497.
105. Thirumamagal, B. T. S.; Johnsamuel, J.; Cosquer, G. Y.; Byun, Y.; Yan, J.; Narayanasamy, S.; Tjarks, W.; Barth, R. F.; Al-Madhoun, A. S.; Eriksson, S. Boronated thymidine analogues for boron neutron capture therapy. Nucleosides Nucleot. Nucleic Acids 2006, 25, 861-866.
106. Narayanasamy, S.; Thirumamagal, B. T. S.; Johnsamuel, J.; Byun, Y.; Al-Madhoun, A. S.; Usova, E.; Cosquer, G. Y., et al., Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer. Bioorg. Med. Chem. 2006, 14, 6886-6899.
107. Tjarks, W.; Tiwari, R.; Byun, Y.; Narayanasamy, S.; Barth, R. F. Carboranyl Thymidine Analogues for Neutron Capture Therapy. Chem. Comm. 2007, 47, 4978-4991.
108. Olejniczak, A. B.; Plešek, J.; Křiž O.; Lesnikowski Z. J. A nucleoside conjugate containing a metallacarborane group and its incorporation into a DNA oligonucleotide. Angew. Chem. Int. Ed. 2003, 43, 5740-5743.
109. Lesnikowski, Z. J.; Paradowska, E.; Olejniczak, A. B.; Studzinska, M.; Seekamp, P.; Schusler, U.; Gabel, D.; Schinazi, R. F.; Plešek. Towards new boron carriers for boron neutron capture therapy: metallacarboranes and their nucleoside conjugates. Bioorg. Med. Chem. 2005, 13, 4168-4175.
110. Renner, M. W.; Miura, M.; Easson, M. W.; Vicente, M. G. H. Recent Progress in the Syntheses and Biological Evaluation of Boronated Porphyrins for Boron Neutron Capture Therapy. Curr. Med. Chem., Anti-Cancer Agents 2006, 6, 145-157.
111. Ol'shevskaya, V. A.; Zaytsev, A. V.; Savchenko, A. N.; Shtil, A. A.; Cheong, C. S.; Kalinin, V. N. Boronated porphyrins and chlorins as potential anticancer drugs. Bull. Korean Chem. Soc. 2007, 28, 1910-1916.
112. Vicente, M. G. H.; Sibrian-Vazquez, M. In The Handbook of Porphyrin Science, Kadish, K. M.; Smith, K. M.; Guilard, R. Eds., Singapore: World Scientific Publishers, 2010, Vol. 4, Chapter 18, pp. 191-248.
113. Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic therapy. J. Natl. Cancer Inst. 1998, 90, 889-905.
114. Pandey, R. K.; Zhang, G. In The Porphyrin Handbook, Kadish, K. M.; Smith, K. M.; Guilard, R. Eds., Boston: Academic Press, 2002; Vol. 6, pp. 157-230.
115. Brown, S.; Brown, E. A.; Walker, I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004, 5, 497-508.
116. Huang, Z. A review of progress in clinical photodynamic therapy. Techn. Cancer Res. Treat. 2005, 4, 283-293.
117. Osterloh, J.; Vicente, M. G. H. Mechanisms of porphyrinoid localization in tumors. J. Porphyrins and Phthalocyanines 2002, 6, 305-324.
118. Haushalter, R. C.; Rudolph, R. W. Meso-Tetracarboranylporphyrins. J. Am. Chem. Soc. 1978, 100, 4628-4629.
119. Haushalter, R. C.; Butler, W. M.; Rudolph, R. W. The Preparation And Characterization Of Several Meso-Tetracarboranylporphyrins. J. Am. Chem. Soc. 1981, 103, 2620-2627.
120. Kahl, S. B.; Koo, M.-S.; Laster, B. H.; Fairchild, R. G. Boronated porphyrins in NCT: Results with a new potent tumor localizer. Strahlenther. Onkol. 1989, 165, 131-134.
121. Miura, M.; Gabel, D.; Fairchild, R. G.; Laster, B. H.; Warkentien, L. S. Synthesis and in vivo studies of a carboranyl porphyrin. Strahlenther. Onkol. 1989, 165, 134-137.
122. Kahl, S. B.; Joel, D. D.; Nawrocky, M. M.; Micca, P. L.; Tran, K. P.; Finkel, G. C.; Slatkin, D. N. Uptake of a nido-carboranylporphyrin by human glioma xenografts in athymic nude-mice and by syngeneic ovarian carcinomas in immunocompetent mice. Proc. Nat. Acad. Sci. USA 1990, 87, 7265-7269.
123. Fairchild, R. G.; Kahl, S. B.; Laster, B. H.; Kalef-Ezra, J.; Popenoe, E. A invitro determination of uptake, retention, distribution, biological efficacy, and toxicity of boronated compounds for neutron-capture therapy-a comparison of porphyrins with sulfhydryl boron hydrides. Cancer Res. 1990, 50, 4860-4865.
124. Hill, J. S.; Kahl, S. B.; Kaye, A. H.; Stylli, S. S.; Koo, M. S.; Gonzales, M. F.; Vardaxis, N. J.; Johnson, C. I. Selective tumor uptake of a boronated porphyrin in an animal-model of cerebral glioma. Proc. Nat. Acad. Sci. USA 1992, 89, 1785-1789.
125. Hill, J. S.; Kahl, S. B.; Stylli, S. S.; Nakamura, Y.; Koo, M.-S.; Kaye, A. H. Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Proc. Natl. Acad. Sci.USA 1995, 92, 12126-12130.
126. Ceberg, C. P.; Brun, A.; Kahl, S. B.; Koo, M. S.; Persson, B. R. R.; Salford, L. G. A comparative-study on the pharmacokinetics and biodistribution of boronated porphyrin (bopp) and sulfhydryl boron hydride (bsh) in the rg2 rat glioma model. J. Neurosurg. 1995, 83,86-92.
127. Tibbitts, J.; Fike, J. R.; Lamborn, K. R.; Bollen, A. W.; Kahl, S. B. Toxicology of a boronated porphyrin in dogs. Photochem. Photobiol. 1999, 69, 587-594.
128. Miura, M.; Micca, P.; Heinrichs, J.; Gabel, D.; Fairchild, R.; Slatkin, D. Biodistribution And Toxicity Of 2,4-divinyl-nido-ortho-carboranyldeuteroporphyrin IX in mice. Biochem. Pharmacol. 1992, 43, 467-476.
129. Miura, M.; Micca, P. L.; Fisher, C. D.; Heinrichs, J. C.; Donaldson, J. A.; Finkel, G. C.; Slatkin, D. N. Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy: Biodistribution and toxicity in tumor-bearing mice. Int. J. Cancer 1996, 68, 114-119.
130. Miura, M.; Micca, P.; Fisher, C.; Gordon, C.; Heinrichs, J.; Slatkin, D.N. Evaluation of carborane-containing porphyrins as tumour targeting agents for boron neutron capture therapy. Br. J. Radiol. 1998, 71, 773-781.
131. Kreimann, E. L.; Miura, M.; Itoiz, M. E.; Heber, E.; Garavaglia, R. N.; Batistoni, D.; Rebagliati, R. J., et al., Biodistribution of a carborane-containing porphyrin as a targeting agent for Boron Neutron Capture Therapy of oral cancer in the hamster cheek pouch. Arch. Oral Biol. 2003, 48, 223-232.
132. Miura, M.; Morris, G. M.; Micca, P. L.; Nawrocky, M. M.; Makar, M. S.; Cook, S. P.; Slatkin, D. N. Synthesis of copper octabromotetracarboranylphenylporphyrin for boron neutron capture therapy and its toxicity and biodistribution in tumour-bearing mice. Br. J. Radiol. 2004, 77, 573-580.
133. Kahl, S. B.; Koo, M. S. Synthesis of tetrakis-carborane-carboxylate esters of 2,4-bis-(a,ß-dihydroxyethyl)-deuteroporphyrin IX. J. Chem. Soc. Chem. Commun. 1990, 24, 1769-1771.
134. Miura, M.; Gabel, D.; Oenbrink, G.; Fairchild, R. G. Preparation of carboranyl porphyrins for boron neutron-capture therapy. Tetrahedron Lett. 1990, 31, 2247-2250.
135. Rosenthal, M. A.; Kavar, B.; Uren, S.; Kaye, A. H. Promising survival in patients with high-grade gliomas following therapy with a novel boronated porphyrin. J. Clin. Neurosci. 2003, 10, 425-427.
136. Bandyopadhyaya, A. K.; Narayanasamy, S.; Barth, R. F.; Tjarks, W. Synthesis of novel texaphyrins containing lanthanides and boron. Tetrahedron Lett. 2007, 48, 4467-4469.
137. Vicente, M. G. H.; Edwards, B. F.; Shetty, S. J.; Hou, Y.; Boggan, J. E. Syntheses and preliminary biological studies of four meso-tetra[(nido-carboranylmethyl)phenyl]porphyrins. Bioorg. Med. Chem. 2002, 10, 481-492.
138. Lauceri, R.; Purrello, R.; Shetty, S. J.; Vicente, M. G. H. Interactions of anionic carboranylated porphyrins with DNA. J. Am. Chem. Soc. 2001, 123, 5835-5836.
139. Vicente, M. G. H.; Gottumukkala, V.; Wickramasinghe, A.; Anikovsky, M.; Rodgers, M. A. Singlet Oxygen Generation and Dark Toxicity of a nido-and a closo-Carboranylporphyrin. J. Proc. SPIE 2004, 5315, 33-40.
140. Bobadova-Parvanova, P.; Oku, Y.; Wickramasinghe, A.; Hall, R. W.; Vicente, M. G. H. Ab initio and 1H NMR study of the Zn(II) complexes of a nido-and a closo-carboranylporphyrin. J. Porphyrins Phthalocyanines 2004, 8, 996-1006.
141. Vicente, M. G. H.; Wickramasinghe, A.; Nurco, D. J.; Wang, H. J. H.; Nawrocky, M. M.; Makar, M. S.; Miura, M. Synthesis, toxicity and biodistribution of two 5,15-di[3,5-(nido-carboranylmethyl)phenyl]porphyrins in EMT-6 tumor bearing mice. Bioorg. Med. Chem. 2003, 11, 3101-3108.
142. Vicente, M. G. H.; Nurco, D. J.; Shetty, S. J.; Osterloh, J.; Ventre, E.; Hegde, V.; Deustch, W. A. Synthesis, dark toxicity and induction of in vitro DNA photodamage by a tetra(4-nido-carboranylphenyl)porphyrin. J. Photochem. Photobiol. B: Biol. 2002, 68, 123-132.
143. Gottumukkala, V.; Ongayi, O.; Baker, D. G.; Lomax, L. G.; Vicente, M. G. H. Synthesis, cellular uptake and animal toxicity of a tetra(carboranylphenyl)-tetrabenzoporphyrin. Bioorg. Med. Chem. 2006, 14, 1871-1879.
144. Fabris, C.; Vicente, M. G. H.; Hao, E.; Friso, E.; Borsetto, L.; Jori, G.; Miotto, G., et al., Tumour-localizing and -photosensitising properties of meso-tetra(4-nido-carboranylphenyl)porphyrin (H2TCP). J. Photochem. Photobiol. B: Biol. 2007, 89, 131-138.
145. Soncin, M.; Friso, E.; Jori, G.; Hao, E.; Vicente, M. G. H.; Miotto, G.; Colautti, P., et al. Tumor-localizing and radiosensitizing properties of meso-tetra(4-nido-carboranylphenyl)porphyrin (H2TCP). J. Porphyrins Phthalocyanines 2008, 12, 866-873.
146. Jori, G.; Soncin, M.; Friso, E.; Vicente, M. G. H.; Hao, E.; Miotto, G.; Colautti, P., et al., A novel boronated-porphyrin as a radio-sensitizing agent for boron neutron capture therapy of tumours: In vitro and in vivo studies. Appl. Rad. Isotopes 2009, 67, S321-S324.
147. Clark, J. C.; Fronczek, F. R.; Vicente, M. G. H. Novel carboranylporphyrins for application in boron neutron capture therapy (BNCT) of tumors. Tetrahedron Lett. 2005, 46, 2365-2368.
148. Easson, M. W.; Fronczek, F. R.; Jensen, T. J.; Vicente, M. G. H. Synthesis and in vitro properties of trimethylamine-and phosphonate-substituted carboranylporphyrins for application in BNCT. Bioorg. Med. Chem. 2008, 16, 3191-3208.
149. Luguya, R.J.; Fronczek, F. R.; Smith, K. M.; Vicente, M. G. H. Carboranylcorroles. Tetrahedron Lett. 2005, 46, 5365-5368.
150. Gottumukkala, V.; Luguya, R.; Fronczek F. R.; Vicente, M. G. H. Synthesis and cellular studies of an octa-anionic 5,10,15,20-tetra[3,5-(nido-carboranylmethyl)phenyl]porphyrin (H2OCP) for application in BNCT. Bioorg. Med. Chem. 2005, 13, 1633-1640.
151. Wu, H. T.; Micca, P. L.; Makar, M. S.; Miura, M. Total syntheses of three copper (II) tetracarboranylphenylporphyrins containing 40 or 80 boron atoms and their biological properties in EMT-6 tumor-bearing mice. Bioorg. Med. Chem. 2006, 14, 5083-5092.
152. Hao, E.; Jensen, T. J.; Courtney, B. H.; Vicente, M. G. H. Synthesis and cellular studies of porphyrin-cobaltacarborane conjugates. Bioconj. Chem. 2005, 16, 1495-1502.
153. Hao, E.; Vicente, M. G. H. Expeditious synthesis of porphyrin-cobaltacarborane conjugates. Chem. Commun. 2005, 1306-1308.
154. Hao, E.; Sibrian-Vazquez, M.; Serem, W.; Garno, J. C.; Fronczek, F. R.; Vicente, M. G. H. Synthesis, aggregation and cellular investigations of porphyrin-cobaltacarborane conjugates. Chem. Eur. J. 2007, 13, 9035-9042.
155. Dozzo, P.; Koo, M. S.; Berger, S.; Forte, T. M.; Kahl, S. B. Synthesis, characterization, and plasma lipoprotein association of a nucleus-targeted boronated porphyrin. J. Med. Chem. 2005, 48, 357-359.
156. Luguya, R.; Fronczek, F. R.; Smith, K. M.; Vicente, M. G. H. Synthesis of novel carboranylchlorins with dual application in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT). App. Rad. Isotopes 2004, 61, 1117-1123.
157. Luguya, R.; Jensen, T. J.; Smith, K. M.; Vicente, M. G. H. Synthesis and cellular studies of a carboranylchlorin for the PDT and BNCT of tumors. Bioorg. Med. Chem. 2006, 14, 5890-5897.
158. Kuchin, R. A. V.; Mal'shakova, M. V.; Belykh, D. V.; Ol'shevskaya, V. A.; Kalinin, V. N. Synthesis of boronated derivatives of chlorin e(6) with amide bond. Dokl. Chem. 2009, 425, 80-83.
159. Ol'shevskaya, V. A.; Nikitina, R. G.; Savchenko, A. N.; Malshakova, M. V.; Vinogradov, A. M.; Golovina, G. V.; Belykh, D. V., et al., Novel boronated chlorin e(6)-based photosensitizers: Synthesis, binding to albumin and antitumour efficacy. Bioorg. Med. Chem. 2009, 17, 1297-1306.
160. Ol'shevskaya, V. A.; Savchenko, A. N.; Zaitsev, A. V.; Kononova, E. G.; Petrovskii, P. V.; Ramonova, A. A.; Tatarskiy, V. V., et al., Novel metal complexes of boronated chlorin e(6) for photodynamic therapy. J. Organomet. Chem. 2009, 694, 1632-1637.
161. Ol'shevskaya, V.; Zaitsev, A.; Savchenko, A.; Kononova, E.; Petrovskii, P.; Kalinin, V. Synthesis of boronated derivatives of pheophorbide a. Dokl. Chem. 2008, 423, 294-298.
162. Luzgina, V. N.; Ol'shevskaya, V. A.; Sekridova, A. V.; Mironov, A. F.; Kalinin, V. N.; Pashchenko, V. Z.; Gorokhov, V. V.; Tusov, V. B.; Shtil, A. A. Synthesis of boron-containing derivatives of pyropheophorbide (a) under-bar and investigation of their photophysical and biological properties. Russ. J. Org. Chem. 2007, 43, 1243-1251.
163. Bregadze, V. I.; Sivaev, I. B.; Lobanova, I. A.; Titeev, R. A.; Brittal, D. I.; Grin, M. A.; Mironov, A. F. Conjugates of boron clusters with derivatives of natural chlorin and bacteriochlorin. Appl. Rad. Isotopes 2009, 67, S101-S104.
164. Mironov, A. F.; Grin, M. A. Synthesis of chlorin and bacteriochlorin conjugates for photodynamic and boron neutron capture therapy. J. Porphyrins Phthalocyanines 2008, 12, 1163-1172.
165. Giuntini, F.; Raoul, Y.; Dei, D.; Municchi, M.; Chiti, G.; Fabris, C.; Colautti, P.; Jori, G.; Roncucci, G. Synthesis of tetrasubstituted Zn(II)-phthalocyanines carrying four carboranyl-units as potential BNCT and PDT agents. Tetrahedron Lett. 2005, 46, 2979-2982.
166. Friso, E.; Roncucci, G.; Dei, D.; Soncin, M.; Fabris, C.; Chiti, G.; Colautti, P., et al., A novel B-10-enriched carboranyl-containing phthalocyanine as a radio-and photo-sensitising agent for boron neutron capture therapy and photodynamic therapy of tumours: in vitro and in vivo studies. Photochem. Photobiol. Sci. 2006, 5, 39-50.
167. Tsaryova, O.; Semioshkin, A.; Wohrle, D.; Bregadze, V. I. Synthesis of new carboran-based phthalocyanimes and study of their activities in the photoxidation of citronellol. J. Porphyrins Phthalocyanines 2005, 9, 268-274.
168. Li, H.; Fronczek, F. R.; Vicente, M. G. H. Synthesis and properties of cobaltacarborane-functionalized Zn(II)-phthalocyanines. Tetrahedron Lett. 2008, 49, 4828-4830.
169. Li, H. R.; Fronczek, F. R.; Vicente, M.G. H. Cobaltacarborane-phthalocyanine conjugates: Syntheses and photophysical properties. J. Organomet. Chem. 2009, 694, 1607-1611.
170. Crossley, E. L.; Ziolkowski, E. J.; Coderre, J. A.; Rendina, L. M. Boronated DNA-binding compounds as potential agents for boron neutron capture therapy. Mini-Rev. Med. Chem. 2007, 7, 303-313.
171. Ghaneolhosseini, H.; Tjarks, W.; Sjoberg, S. Synthesis of novel boronated acridines-and spermidines as possible agents for BNCT. Tetrahedron 1998, 54, 3877-3884.
172. Bateman S. A.; Kelly, D. P.; Martin, R. F,; White, J. M. DNA binding compounds. VII. Synthesis, characterization and DNA binding capacity of 1,2-dicarba-closo-dodecarborane bibenzimidazoles related to the DNA minor groove biner Hoechst 33258. Aust. J. Chem. 1999, 52, 291-301.
173. Gedda, L.; Ghaneolhosseini, H.; Nilsson, P.; Nyholm, K.; Pettersson, J.; Sjoberg, S.; Carlsson, J. DNA binding compounds. VII -Synthesis, characterization and DNA binding capacity of 1,2-dicarba-closo-dodecaborane bibenzimidazoles related to the DNA minor groove binder Hoechst 33258. Anti-Cancer Drug Design 2000, 15, 277-286.
174. Woodhouse, S. L.; Ziolkowski, E. J.; Rendina, L. M. Synthesis and anti-cancer activity of dinuclear platinum(II) complexes containing bis(thioalkyl)dicarba-closo-dodecaborane(12) ligands. J. Chem. Soc., Dalton Trans. 2005, 2827-2829.
175. Woodhouse, S. L.; Rendina, L. M. Multinuclear platinum(II)-amine complexes containing bis(aminopropyl)dicarba-closo-dodecaborane(12) ligands. J. Chem. Soc., Dalton Trans. 2004, 21, 3669-3677.
176. Adams, D. M.; Ji, W.; Barth, R. F.; Tjarks, W. Comparative in vitro evaluation of dequalinium B, a new boron carrier for neutron capture therapy (NCT). Anticancer Res. 2000, 20, 3395-3402.
177. Zakharkin, L. I.; Ol'shevskaya, V. A.; Spryshkova, R. A.; Grigor'eva, E. Y.; Ryabkova, V. I.; Borisov, G.I. Synthesis of bis(dialkylaminomethyl)-o-and m-carboranes and study of these compounds as potential preparations for boron neutron capture therapy. Pharm. Chem. J. 2000, 34, 301-304.
178. El-Zaria, M. E.; Doerfler, U.; Gabel, D. J. Synthesis of [(aminoalkylamine)-N-amino-alkyl]azanonaborane( 11) derivatives for boron neutron capture therapy. J. Med. Chem. 2002, 45, 5817-5819.
179. Yang, W.; Barth, R. F.; Wu, G.; Tjarks, W.; Binns, P.; Riley, K. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl. Rad. Isotopes 2009, 67, S328-S331.
180. Wu, G.; Yang, W.; Barth, R. F.; Kawabata, S.; Swindall, M.; Bandyopadhyaya, A. K.; Tjarks, W., et al., Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 2007, 13, 1260-1268.
181. Yang, W.; Wu, G.; Barth, R. F.; Swindall, M. R.; Bandyopadhyaya, A. K.; Tjarks, W.; Tordoff, K., et al., Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 2008, 14, 838-891.
182. Backer, M. V.; Gaynutdinov, T. I.; Patel, V. P.; Bandyopadhyaya, A. K.; Thirumamagal, B. T. S.; Tjarks, W.; Barth, R. F.; Claffey, K.; Backe, J. M. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Therap. 2005, 4, 1423-1429.
183. Yang, W.; Barth, R. F.; Wu, G.; Kawabata, S.; Sferra, T. J.; Bandyopadhyaya, A. K.; Tjarks, W., et al., Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Clin. Cancer Res. 2006, 12, 3792-3802.
184. Feng, B.; Tomizawa, K.; Michiue, H.; Miyatake, S-I.; Han, X-J.; Fujimura, A.; Seno, M.; Kirihata, M.; Matsui, H. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009, 30, 1746-1755.
185. Pan, X.; Gong, W.; Yang, W.; Barth, R. F.; Tjarks, W.; Lee, R. J. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjugate Chem. 2007, 18, 101-108.
186. Yanagie, H.; Maruyama, K.; T. Takizawa, T.; Ishida, O.; Ogura, K.; Matsumoto, T.; Sakurai, Y., et al., Application of boron-entrapped stealth liposomes to inhibition of growth of tumour cells in the in vivo boron neutron-capture therapy model. Biomed. Pharmacotherapy 2006, 60, 43-50.
187. Altieri, S.; Balzi, M.; Bortolussi, S.; Bruschi, P.; Ciani, L.; Clerici, A. M.; Faraoni, P., et al., Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J. Med.Chem. 2009, 52, 7829-7835.
188. Ito, Y.; Kimura, Y.; Shimahara, T.; Ariyoshi, Y.; Shimahara, M.; Miyatake, S.; Kawabata, S.; Kasaoka, S; Ono, K. Disposition of TF-PEG-Liposome-BSH in tumor-bearing mice. Appl. Rad. Isotopes 2009, 67, S109-S110.
189. Watson-Clark, R. A.; Banquerigo, M. L.; Shelly, K.; Hawthorne, M. F.; Brahn, E. Model studies directed toward the application of boron neutron capture therapy to rheumatoid arthritis: Boron delivery by liposomes in rat collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 1998, 95, 2531-2534.
190. Li, T.; Hamdi, J.; Hawthorne, M. F. Unilamellar liposomes with enhanced boron content. Bioconjugate Chem. 2006, 17, 15-20.
191. Miyajima, Y.; Nakamura, H.; Kuwata, Y.; Lee, J-D.; Masunaga, S; Ono, K.; Maruyama, K. Transferrin-loaded nido-carborane liposomes: Tumor-targeting boron delivery system for neutron capture therapy. Bioconjugate Chem. 2006, 17, 1314-1320.
192. Doi, A.; Kawabata, S.; Iida, K.; Yokoyama, K.; Kajimoto, Y.; Kuroiwa, T.; Shirakawa T., et al. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J. Neurooncol. 2008, 87, 287-294.
193. Thirumamagal, B. T. S.; Zhao, X. B.; Bandyopadhyaya, A. K.; Narayanasamy, S.; Johnsamuel, J.; Tiwari, R.; Golightly, D. W., et al., Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjugate Chem. 2006, 17, 1141-1150.
194. Zhu, Y.; Yan, K. C.; Maguire, J. A.; Hosmane, N. S. Recent Developments in the Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology. Curr. Chem. Biol. 2007, 1, 141-149.
195. Wu, G.; Barth, R. F.; Yang, W.; Lee, R. J.; Tjarks, W.; Backer, M. V.; Backer, J. M. In Neutron capture therapy of cancer: Nanoparticles and high molecular weight boron delivery agents in Nanotechonolgy for cancer therapy. Mansoor M. Amiji (Ed.), CRC Press, 2006, Chapter 6, pp. 77-103.